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Rhodotorula species are emergent fungal pathogens capable of causing invasive infections, primarily fungemia. They are particu-
larly problematic in immunosuppressed patients when using a central venous catheter. In this study, we evaluated the species
distribution of 51 clinical and 8 environmental Rhodotorula species isolates using the ID32C system and internal transcribed
spacer (ITS) sequencing. Antifungal susceptibility testing and biofilm formation capability using a crystal violet staining assay
were performed. Using ITS sequencing as the gold standard, the clinical isolates were identified as follows: 44 R. mucilaginosa
isolates, 2 R. glutinis isolates, 2 R. minuta isolates, 2 R. dairenensis isolates, and 1 Rhodosporidium fluviale isolate. The environ-
mental isolates included 7 R. mucilaginosa isolates and 1 R. slooffiae isolate. Using the ID32C system, along with a nitrate assim-
ilation test, only 90.3% of the isolates tested were correctly identified. In the biofilm formation assay, R. mucilaginosa and R.
minuta exhibited greater biofilm formation ability compared to the other Rhodotorula species; the clinical isolates of R. muci-
laginosa showed greater biofilm formation compared to the environmental isolates (P 0.04). Amphotericin B showed good in
vitro activity (MIC< 1g/ml) against planktonic cells, whereas voriconazole and posaconazole showed poor activity (MIC50/
MIC90, 2/4g/ml). Caspofungin and fluconazole MICs were consistently high for all isolates tested (>64g/ml and> 4g/ml,
respectively). In this study, we emphasized the importance of molecular methods to correctly identify Rhodotorula species iso-
lates and non-R. mucilaginosa species in particular. The antifungal susceptibility profile reinforces amphotericin B as the anti-
fungal drug of choice for the treatment of Rhodotorula infections. To our knowledge, this is the first study evaluating putative
differences in the ability of biofilm formation among different Rhodotorula species.
Rhodotorula species are basidiomycetous yeasts that are widelydistributed in nature. They have been isolated from a variety
of environmental sources, including soil, air, aquatic ecosystems,
plants, and fruits. In humans, these yeasts have been isolated from
the nails, skin, sputum, urine, feces, and hands of health care
workers (1–3). Rhodotorula species were traditionally considered
to be nonvirulent saprophytes and common contaminant micro-
organisms. However, in the last 2 decades, these yeasts have
emerged as opportunistic pathogens (4–7).
The increase in invasive fungal infections caused by emergent
pathogens is related to several factors, including the increased oc-
currence of degenerative and malignant diseases in different pop-
ulations, as well as the increased number of patients that undergo
organ transplantation, immunosuppressive therapies, broad-
spectrum antibiotic therapy, and invasive medical procedures (5,
6, 8). In addition, the availability of new tools for the identification
of microorganisms has certainly played a role in the ever-increas-
ing capability of labs to recognize emergent pathogens.
Invasive infections caused by Rhodotorula species are mostly
associated with underlying immunosuppression or cancer and
with the use of central venous catheters (CVCs) and other im-
plantable medical devices. The most frequent infection caused by
Rhodotorula species is fungemia, followed by eye infections, peri-
tonitis, and meningitis (4, 7, 9–11).
Although Rhodotorula species are responsible for a small per-
centage of all nosocomial acquired fungemia, this pathogen has
been reported as the third most common yeast isolated from
blood cultures (9) and as the fourth most common infectious
fungus according to the ARTEMIS Global Antifungal Surveillance
Program (12). Overall, R. mucilaginosa, R. glutinis, and R. minuta
have been recognized as the three most clinically relevant species
of Rhodotorula isolated from blood cultures (4, 7, 12).
Conventional phenotypic methods are limited in accuracy and
consistency for species identification of emergent pathogens, in-
cluding Rhodotorula species (9, 13–17). Thus, limited published
data are available on the species distribution of Rhodotorula spe-
cies that cause invasive infections and the antifungal susceptibili-
ties of Rhodotorula species isolates correctly identified by molec-
ular methods.
In this study, we evaluated the species distribution of 51 clinical
and 8 environmental Rhodotorula species isolates by using inter-
nal transcribed spacer (ITS) sequencing and by testing the anti-
fungal susceptibilities of clinicalRhodotorula species isolates using
the CLSI broth microdilution assay. In addition, we investigated
the biofilm formation capabilities of different Rhodotorula spe-
cies.
MATERIALS AND METHODS
Microorganisms.We initially tested 59 yeast isolates previously identified
as Rhodotorula species, including 51 clinical and 8 environmental isolates
recovered from 14 different Brazilian hospitals during the period from
1995 to 2010. The 51 clinical strains included 39 samples obtained from
blood cultures and 12 samples from different anatomical sites. Clinical
strains were isolated from 50 different patients, and the yeasts were sent to
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the Laboratório Especial de Micologia, Universidade Federal de São
Paulo, São Paulo, Brazil, for identification and antifungal susceptibility
testing. Reference strains of R. mucilaginosa (CBS 329), R. pallida (CBS
320), and R. glutinis (CBS 20) were also included as control organisms in
all laboratory tests, totaling 62 Rhodotorula species isolates.
Screening of Rhodotorula species by conventional methods. Yeast
isolates from stock cultures were initially plated on Sabouraud dextrose
agar (SDA) (Difco; BD and Company) and incubated at 35°C for 48 h to
ensure purity and viability.Rhodotorula species isolates were screened based
on the texture and typical color exhibited by their colonies on SDA, as well as
by their micromorphology after culturing each isolate on cornmeal-Tween 80
agar. All isolates that were able to produce carotenoid pigments conferring a
salmon-pink to coral-red color to the colonies and presenting only spheroidal
to oval budding cells without the rudimentary formation of hyphae were
considered to belong to the genus Rhodotorula (18, 19).
Microorganism identification using amplification and sequencing
of the ITS region of ribosomal DNA (rDNA). The genomic DNA was
extracted using mechanical disruption with glass beads combined with the
SDS-based enzymatic lysis method adapted from Wach et al. (20). PCR
and sequencing were performed with the universal primers ITS1 and ITS4
as described previously, and amplicons were sequenced using the dide-
oxynucleotide method in an ABI Prism 3100 automated sequencer (Ap-
plied Biosystems, CA) (21, 22). The DNA sequences generated were edited
using Sequencher 4.1.4 (Genes Code Co., MI) to obtain contigs for each
sample. Species identification was performed using the Basic Local Align-
ment Search Tool (BLAST) (http://blast.ncbi.nlm.nih.gov); an E value of
105 was used as the cutoff for species identification.
Biochemical profile of yeasts evaluated by the ID32C galleries.All of
the yeasts were tested by the ID32C system (bioMérieux, Marcy l’Etoile,
France), along with a nitrate assimilation test, for species-level identifica-
tion of Rhodotorula isolates. The tests were performed rigorously accord-
ing to the manufacturer’s instructions. The galleries were incubated at
30°C for 72 h in an airtight box containing a small volume of water to
create a humid atmosphere. The carbohydrate assimilation profile ob-
tained for each tested isolate was compared to the database apiweb version
3.0 (bioMérieux, Marcy l’Etoile, France) to obtain the final yeast identifi-
cation. The complementary nitrate assimilation tests were performed by cul-
turing the isolates on yeast carbon agar, to which potassium nitrate and pep-
tone were added as nitrogen test sources, at 30°C for up to 7 days (15, 23).
In vitro susceptibility testing. Antifungal susceptibility testing was
performed using the broth microdilution method according to the Clin-
ical and Laboratory Standards Institute (CLSI) document M27-A3 (24).
The antifungal agents and concentrations tested included the following:
0.125 to 64 g/ml for fluconazole (FLC) (Pfizer, Inc., NY) and 0.03 to 16
g/ml for amphotericin B (AMB) (Sigma Chemical Corporation, St.
Louis, MO), caspofungin (CAS) (Merck & Co., Inc., Rahway, NJ), po-
saconazole (PSC) (Schering Plough Research Institute, Kenilworth, NJ),
and voriconazole (VRC) (Pfizer Inc., NY). The antifungal compounds
were provided as pure powders by the manufacturer. All of the plates were
prepared with RPMI 1640 medium buffered with 0.165 M morpho-
linepropanesulfonic acid at pH 7.0 and frozen at20°C until use.
The microplates were incubated at 35°C for 72 h. The MICs were
determined visually after 48 h and 72 h of incubation. Candida krusei
ATCC 6258 and Candida parapsilosis ATCC 22019 were used as quality
control strains. The MIC endpoint for AMB was considered to be the
lowest tested drug concentration able to prevent any visible growth. The
MICs for CAS, FLC, PSC, and VRC were based on a prominent decrease
(50%) in growth compared to that of the drug-free growth control.
The MICs at which 50% (MIC50) and 90% (MIC90) of the tested isolates
were inhibited for each drug after 72 h at 35°C were also determined.
Biofilm production assays. (i) Growth conditions and biofilm for-
mation. The biofilm formation assay was adapted from previously de-
scribed methods (25). The strains initially cultured in SDA at 35°C for 48
h were further subcultured into RPMI 1640 broth and grown for 24 h with
shaking at 200 rpm at 37°C. The cell cultures were harvested, washed twice
with phosphate-buffered saline (PBS), and adjusted to a concentration of
107 cells/ml in RPMI 1640 medium. Biofilm formation was tested in ster-
ile 96-well polystyrene flat-bottom plates (Techno Plastic Products, Swit-
zerland).
For the attachment phase, 100l of the cell suspension was transferred
to each well of the plates and then incubated at 37°C for 1 h 30 min at 75
rpm. Unattached cells were removed, the wells were washed twice with
150 l of PBS, and 150 l of fresh RPMI 1640 medium was added. The
plate was incubated at 37°C for 72 h, with shaking at 75 rpm to allow
biofilm growth. A test medium without cells was added to the final col-
umn of each plate and used as a negative control.
(ii) Biofilm quantification by CV staining. After biofilm formation,
each well was washed twice with 150l PBS, and the plate was dried for 20
min at 35°C. The washed biofilms were stained with 110l of 0.4% aque-
ous crystal violet (CV) solution for 45 min. Afterwards, the wells were
washed three times with 200l of Milli-Q sterile water and destained with
200 l of 95% ethanol. After 45 min, 100 l of destaining solution from
each sample was transferred to a new plate and measured with a spectro-
photometer plate reader (model 680; Bio-Rad) at 570 nm. The absorbance
values (A570) of the negative controls (containing no cells) were sub-
tracted from the values of the test wells to minimize background interfer-
ence. Each strain was tested five times on three different days, and the
biofilm production quantities were reported as the arithmetic means 
standard deviations (SD) of the A570 values for 15 replicate tests.
(iii) Scanning electron microscopy (SEM). Biofilms were formed on
sterile polyvinyl chloride (PVC) strips (surface area, 0.5 cm2) and placed
in 24-well microtiter plates (Techno Plastic Products, Switzerland) as de-
scribed previously. Biofilms formed on PVC strips were fixed overnight at
4°C with 4% formaldehyde plus 2% glutaraldehyde buffered at pH 7.2
with 0.1 M sodium cacodylate. After fixation, the samples were treated
with 1% osmium tetroxide in cacodylate buffer for 1 h. Subsequently, the
samples were treated with 1% tannic acid for 45 min, washed three times
with distilled water for 15 min, and treated again with 1% osmium tetrox-
ide in cacodylate buffer for 1 h. The samples were dehydrated with a
graded series of ethanol washes, critical-point dried in CO2, coated with
gold, and examined with a JEOL JSM-5300 scanning electron microscope
(26).
(iv) Statistical analysis. For a comparison of the biofilm formation
capability between clinical and environmental strains of R. mucilaginosa,
mean A570 values obtained for each group were compared using Student’s
t test with the GraphPad Prism version 5.00 for Windows (GraphPad
Software, CA). A P value of 0.05 was considered significant. Possible
outliers were determined by Grubb’s test using a P value of0.05 as the
cutoff with GraphPad software. The test was performed until no outliers
were detected in the replicates. Outliers were excluded from the analysis.
Nucleotide sequence accessionnumbers.The sequences generated in
this study have been deposited in the GenBank (NCBI) database under the
following accession numbers: JX499189, JX512667, JX512677, JX512680,
JX512681, JX512682, JX512683, JX512684, JX512685, JX512686,
JX512687, JX512688, JX512689, JX512690, JX512691, JX512692,
JX512693, JX512694, JX512695, JX512696, JX512697, JX512698,
JX512699, JX512700, JX512701, JX512702, JX512703, JX512704,
JX512705, JX512706, JX512707, JX512708, JX512709, JX512710,
JX512711, JX512712, JX512713, JX512714, JX512715, JX499188,
JX512668, JX512669, JX512670, JX512671, JX512672, JX512673,
JX512674, JX512675, JX512676, JX512678, JX512679, JX272795,
JX272796, JX494370, JX494371, JX494373, JX494375, JX494374, and
JX494372.
RESULTS
Screening of Rhodotorula species by conventional methods. All
59 yeast isolates tested in this study plus the three reference strains
were pure and viable. The individual colonies exhibited a salmon-
pink to coral-red color on SDA and presented only spheroidal to
oval blastoconidia with the absence of hyphae on corn meal-
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Tween 80 agar. Thus, all isolates were considered to belong to the
genus Rhodotorula.
Molecular identification of Rhodotorula species isolates by
sequencing the ITS region of rDNA. ITS sequencing was used as
the gold standard for the species-level identification of all clinical
and environmental Rhodotorula species isolates tested. DNA se-
quences of approximately 560 bp were obtained for all isolates
tested. The sequences were subjected to BLAST searches to con-
firm the preliminary identification of the strains. BLAST align-
ments with the ITS sequences were successful in identifying all
Rhodotorula species isolates, including the reference strains (100%
query coverage, 99% identity, and an E value of 0.0 for all iso-
lates). The 51 clinical isolates previously screened as Rhodotorula
species were identified as the following: 44 R. mucilaginosa iso-
lates, 2 R. glutinis isolates, 2 R. minuta isolates, 2 Rhodotorula
dairenensis isolates, and 1 Rhodosporidium fluviale isolate. The en-
vironmental isolates were identified as R. mucilaginosa (n  7)
and Rhodotorula slooffiae (n 1) (Table 1).
Biochemical profile of Rhodotorula species isolates evalu-
ated by ID32C and a nitrate assimilation test. Using ITS identi-
fication as a reference, 56 out of the 62 (90.3%) isolates tested,
including the reference strains, were correctly identified to the
species level by the ID32C system combined with the nitrate as-
similation test. However, even after the addition of the nitrate
assimilation test, the ID32C resulted in discrepancies for 5 (8.1%)
of the strains: 2 R. dairenensis strains were misidentified as R.
mucilaginosa, 1 Rhodosporidium fluviale strain was misidentified
as R. glutinis, 1 R. slooffiae strain was misidentified as R. minuta,
and the reference R. pallida strain (CBS 320) did not assimilate
nitrate and was identified with low discrimination between R.
glutinis and the species Candida sphaerica and Candida sake
(Table 2). This particular strain was phenotypically identified
as a Rhodotorula species based on the salmon-pink color of the
colonies and the compatible micromorphology. Moreover, 1
(1.6%) R. minuta isolate (2145) presented an unacceptable profile
for final ID32C identification.
The ID32C system reported the final yeast species identifica-
tion of 9 isolates without requesting the complementary nitrate
assimilation test. These results were obtained with 1 R. minuta
isolate and 2 R. glutinis isolates that were correctly identified and 6
other isolates that were misidentified, including 4 R. mucilaginosa
isolates that were misidentified as R. glutinis, 1 R. slooffiae isolate
that was misidentified as R. minuta, and 1 Rhodosporifium fluviale
isolate that was misidentified as R. glutinis. For these isolates, after
running the ID32C system combined with the nitrate assimilation
test, all 4 R. mucilaginosa isolates originally misidentified as R.
glutinis had a final identification corrected to R. mucilaginosa.
Of note, 37 out of the 52 (71.2%) R.mucilaginosa isolates iden-
tified by the ID32C system along with the nitrate assimilation test
generated the codes 5461750113 and 5461750111. Apparently,
both carbohydrate assimilation profiles are reliable in the identi-
fication of R. mucilaginosa isolates.
A single yeast clinical isolate molecularly identified as Rho-
dosporidium fluviale was excluded from further experiments.
Biofilm formation by Rhodotorula species isolates. The CV
staining assay for the quantification of biofilm formation of the re-
maining 61Rhodotorula species strains tested, including the reference
strains, had absorbance values at 570 nm (A570), ranging from 0.007
to 1.739. To better illustrate the differences in biofilm formation ca-
pability among isolates of Rhodotorula species, we arbitrarily estab-
lished three categories for the quantification of biofilm production:
low (A570,0.160), medium (A570, 0.160 to 0.632), and high (A570,
0.632). These categories were defined based on the quartile values
of the full range of Rhodotorula species A570 values.
The rank scale for Rhodotorula species biofilm formation de-
termined by CV staining was as follows: R. minuta R. mucilagi-
nosa  R. glutinis  R. slooffiae  R. pallida  R. dairenensis.
According to the interpretive criteria adopted in this study, R.
minuta and R. mucilaginosa were classified as medium biofilm
producers, while the isolates from the remaining species were con-
sidered low biofilm producers (Fig. 1).
In addition, clinical isolates of R. mucilaginosa showed higher
biofilm formation capability than that of environmental isolates
(Fig. 2). The clinical isolates exhibited an A570 value of 0.497 
0.353 (mean  SD), and the environmental isolates had an A570
value of 0.210 0.109 (P 0.04).
Of note, during the period from 1997 to 2010, the storage time
at70°C for allR.mucilaginosa isolates did not affect their biofilm
formation capability (data not shown).
Biofilm SEM. SEM images of the biofilms were used to validate
the CV staining interpretive criteria used in our study to quantify the
biofilms of Rhodotorula species isolates. For SEM, we used three iso-
lates representing high, medium, and low biofilm producers: isolate
2991B (A570  1.739), isolate 3166 (A570  0.394), and isolate 320
(A570  0.072). It was possible to verify in the SEM images (Fig. 3)
that isolate 2991B (Fig. 3E and F) had a higher level of biofilm forma-
tion than isolate 3166 (Fig. 3C and D). The isolate 320 presented only
microcolonies that did not have the multilayered architecture of a
mature biofilm (Fig. 3A and B). An examination of the SEM images
revealed that the degree of biofilm formation by high, medium, and
low producers was highly correlated to the results of the CV assay.
Susceptibilities of clinical isolatesofRhodotorula species to5
antifungal agents. Table 3 summarizes the MIC50, MIC90, and
MIC ranges (g/ml) obtained for the Rhodotorula species isolates
for the five antifungal agents after 48 and 72 h of incubation.
The MICs of the 50 clinical isolates of Rhodotorula species after
72 h of incubation ranged from 0.5 to 1 g/ml for AMB, 4 to16
g/ml for CAS, 0.25 to 4g/ml for VRC, 1 to 8g/ml for PSC, and
64 g/ml for FLC.
Of note, all Rhodotorula species isolates tested exhibited AMB
MICs of 1 g/ml. The CAS MICs for all isolates were consis-
tently high (MIC  4 g/ml). The VRC and PSC MICs were
similar (MIC50/MIC90, 2/4g/ml). The FLC MICs were very high
for all isolates tested (64 g/ml).
TABLE 1 Species distribution of clinical and environmental isolates of
Rhodotorula species identified by ITS sequencing
Species
No. of isolates from:
TotalBlood culture Other sourcea Environment
R. mucilaginosa 34 10 7 51
R. minuta 2   2
R. glutinis  2  2
R. dairenensis 2   2
R. slooffiae   1 1
Total 38 12 8 58
a Other sources include pleural fluid, bronchoalveolar lavage, skin biopsy, secretion
from a fistula hand, nasal mucus, scalp, sole of the foot, and catheter.
Nunes et al.
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DISCUSSION
Rhodotorula species is an emergent pathogen capable of causing in-
vasive infections in humans, particularly in immunocompromised
patients (7, 9, 27–29). In spite of the increased number of invasive
infections byRhodotorula species described in the last decades, only a
small number of epidemiological studies have used molecular meth-
ods for the identification of Rhodotorula species. To our knowledge,
this is the first study in which ITS sequencing was used as the gold
standard for the species-level identification of a large collection of
clinical and environmental Rhodotorula species isolates.
TABLE 2 Concordance between the genotypic and phenotypic identification of 62 yeast isolates previously identified as Rhodotorula speciesa
Isolate Source
ITS sequencing ID32C system nitrate assimilation
Yeast species Accession no. Yeast species Identification code
16 Blood culture R. mucilaginosa JX499189 R. mucilaginosa 5461750113
17 Blood culture R. mucilaginosa JX512667 R. mucilaginosa 5461750311
230* Blood culture R. dairenensis JX512677 R. mucilaginosa 5061710113
281 Blood culture R. mucilaginosa JX512680 R. mucilaginosa 5461750113
320 Blood culture R. mucilaginosa JX512681 R. mucilaginosa 5461750111
369* Blood culture Rhodosporidium fluviale JX512682 R. glutinis 5465750313
467 Blood culture R. mucilaginosa JX512683 R. mucilaginosa 7461750111
701 Blood culture R. mucilaginosa JX512684 R. mucilaginosa 5461750111
702 Blood culture R. mucilaginosa JX512685 R. mucilaginosa 5461750113
717 Blood culture R. mucilaginosa JX512686 R. mucilaginosa 5461750113
740 Blood culture R. mucilaginosa JX512687 R. mucilaginosa 5461750111
755 Blood culture R. mucilaginosa JX512688 R. mucilaginosa 5461750111
800 Blood culture R. mucilaginosa JX512689 R. mucilaginosa 5461750111
803 Blood culture R. mucilaginosa JX512690 R. mucilaginosa 5461750111
808 Blood culture R. mucilaginosa JX512691 R. mucilaginosa 5461710113
1385 Blood culture R. mucilaginosa JX512692 R. mucilaginosa 5461750111
1765 Blood culture R. mucilaginosa JX512693 R. mucilaginosa 5461750111
2145* Blood culture R. minuta JX512694 Unacceptable profile 5313514331
2265 Blood culture R. mucilaginosa JX512695 R. mucilaginosa 5461750113
2334B Blood culture R. mucilaginosa JX512696 R. mucilaginosa 5061550313
2413 Blood culture R. mucilaginosa JX512697 R. mucilaginosa 5461750111
2495 Blood culture R. mucilaginosa JX512698 R. mucilaginosa 5461650111
2552 Blood culture R. mucilaginosa JX512699 R. mucilaginosa 5061350113
2595 Blood culture R. mucilaginosa JX512700 R. mucilaginosa 5461750111
2675 Blood culture R. mucilaginosa JX512701 R. mucilaginosa 5461750113
2708 Blood culture R. mucilaginosa JX512702 R. mucilaginosa 5461750113
2795 Blood culture R. minuta JX512703 R. minuta 4513314331
2843A Blood culture R. mucilaginosa JX512704 R. mucilaginosa 7461360113
2945* Blood culture R. dairenensis JX512705 R. mucilaginosa 5421710013
2984 Blood culture R. mucilaginosa JX512706 R. mucilaginosa 5461750111
2988 Blood culture R. mucilaginosa JX512707 R. mucilaginosa 5461750113
2991B Blood culture R. mucilaginosa JX512708 R. mucilaginosa 5461750113
3020 Blood culture R. mucilaginosa JX512709 R. mucilaginosa 5461750113
3051 Blood culture R. mucilaginosa JX512710 R. mucilaginosa 5021610003
3166 Blood culture R. mucilaginosa JX512711 R. mucilaginosa 5461750113
3201 Blood culture R. mucilaginosa JX512712 R. mucilaginosa 5461750113
3225 Blood culture R. mucilaginosa JX512713 R. mucilaginosa 5461750113
6190 Blood culture R. mucilaginosa JX512714 R. mucilaginosa 5461750113
6437 Blood culture R. mucilaginosa JX512715 R. mucilaginosa 5461750113
04B Secretion from a fistula hand R. mucilaginosa JX499188 R. mucilaginosa 5061750113
130 Bronchoalveolar lavage R. mucilaginosa JX512668 R. mucilaginosa 5461750113
131 Bronchoalveolar lavage R. mucilaginosa JX512669 R. mucilaginosa 5461750111
132A Bronchoalveolar lavage R. mucilaginosa JX512670 R. mucilaginosa 5461750113
150 Scalp R. glutinis JX512671 R. glutinis 7067750113
157 Sole of the foot R. glutinis JX512672 R. glutinis 7067750113
214 Nasal mucus R. mucilaginosa JX512673 R. mucilaginosa 5441750113
215 Pleural fluid R. mucilaginosa JX512674 R. mucilaginosa 5461750113
216 Pleural fluid R. mucilaginosa JX512675 R. mucilaginosa 5461750113
221 Pleural fluid R. mucilaginosa JX512676 R. mucilaginosa 5461750113
258 Skin biopsy R. mucilaginosa JX512678 R. mucilaginosa 5061750113
279 Catheter R. mucilaginosa JX512679 R. mucilaginosa 5461640101
9amb Env. R. mucilaginosa JX272795 R. mucilaginosa 5461750113
10amb Env. R. mucilaginosa JX272796 R. mucilaginosa 5461750111
11amb Env. R. mucilaginosa JX494370 R. mucilaginosa 5461750113
14amb Env. R. mucilaginosa JX494371 R. mucilaginosa 5061750113
3560 Env. R. mucilaginosa JX494373 R. mucilaginosa 5461750113
3630* Env. R. slooffiae JX494375 R. minuta 4513214311
3988A Env. R. mucilaginosa JX494374 R. mucilaginosa 7061750113
15amb Env. R. mucilaginosa JX494372 R. mucilaginosa 5461750113
CBS 20 CBS R. glutinis R. glutinis 5061310013
CBS 320* CBS R. pallida Rhodotorula sp. 7067350113
CBS 329 CBS R. mucilaginosa R. mucilaginosa 5661750311
a Isolates that showed differences between the phenotypic and genotypic identifications are marked with an asterisk. The identification codes in bold represent the two most
common biochemical profiles among all R. mucilaginosa isolates tested. Env., air from hospital environment; CBS, reference strains.
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ITS sequencing was a reliable method for the identification of
Rhodotorula species, and it was more accurate than conventional
phenotypic tests. In our study, the Rhodotorula species distribu-
tion among clinical isolates was similar to that reported previ-
ously: R. mucilaginosa (n 44; 88%) was the most prevalent spe-
cies, followed by R. glutinis (n  2; 4%), R. minuta (n  2; 4%),
and R. dairenensis (n 2; 4%) (7, 9). It is worth mentioning that
there are no reports in the literature regarding infections caused
by the species R. dairenensis and Rhodosporidium fluviale. In ad-
dition, R. mucilaginosa was also the most prevalent species found
among environmental samples, suggesting that this species is well
adapted to both free-living growth and human hosts.
According to the CBS site (http://www.cbs.knaw.nl), Rho-
dosporidium diobovatum, Rhodosporidium sphaerocarpum, and
Rhodosporidium toruloides represent sexual forms of R. glutinis.
Indeed, the ITS sequences of our clinical isolates, 150 and 157,
matched the sequences of R. glutinis and Rhodosporirium diobova-
tum when BLAST searches were performed. These BLAST
matches showed the same scores for all variables, including the E
value, max score, and max identity. Because both taxa appeared to
be the same species, we considered the final identification of the
isolates 150 and 157 to be R. glutinis.
Currently, yeast identification in clinical laboratories is per-
formed using commercial and automated systems (ID32C and
Vitek 2, respectively). These systems show high accuracy for the
FIG 2 Boxplots of the absorbance values obtained for the clinical and environ-
mental isolates of R. mucilaginosa in the biofilm formation assays. The clinical
isolates presented a greater ability to form biofilms than did the environmental
isolates (P0.04). The solid circle indicates the mean absorbance obtained for the
group of clinical (A570, 0.497) and environmental (A570, 0.21) isolates. The asterisk
indicates that isolate 2991B showed significantly greater biofilm formation capa-
bility (P 0.05).
FIG 1 Biofilm production of 61 Rhodotorula species isolates, including the reference strains of R. mucilaginosa (CBS 329), R. pallida (CBS 320), and R. glutinis
(CBS 20). The histograms represent the means SD of the absorbance values at 570 nm (A570) obtained from 15 replicate tests for each sample. According to the
interpretive criteria adopted in this study, R. mucilaginosa (mean A570, 0.449) and R. minuta (mean A570, 0.543) were classified as medium biofilm producers,
whereas the other species of Rhodotorula were considered low biofilm producers (A570,0.160).
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identification of the most common yeast species causing human
infections, such as Candida species. However, they are unable to
distinguish genetically similar species such as the Candida parap-
silosis species complex and show limited accuracy for identifica-
tion of emergent pathogens, including Trichosporon species and
Rhodotorula species (9, 13–17).
Despite a number of limitations, the ID32C system along with
a nitrate assimilation test was able to correctly identify 90.3% of
Rhodotorula species isolates. The complementary nitrate assimila-
tion test was crucial to the final species identification, suggesting
that this test should be performed even when not requested by the
ID32C system report. Inconsistent results in phenotypic identifi-
cation were mostly related to non-R. mucilaginosa isolates. In-
deed, the database of the commercial system ID32C does not in-
clude all species in the genera Rhodotorula and Rhodosporidium.
Rhodotorula species infections are frequently associated with
the presence of CVCs and other implantable medical devices (9–
11, 30). These devices provide the necessary surfaces for biofilm
formation and are currently responsible for a significant percent-
age of human infections. In contrast to the extensive literature
dealing with Candida species biofilms (25, 26, 31–33), little atten-
tion has been paid to emergent fungal pathogens such as Rhodoto-
rula species.
This is the first study to evaluate the biofilm formation ability
of different Rhodotorula species and the putative differences be-
tween clinical and environmental isolates. Using CV staining, we
were able to demonstrate that clinical isolates of R. mucilaginosa
were better at forming biofilms than the environmental isolates.
Moreover, we verified thatR.mucilaginosa andR.minutawere the
best biofilm producers.
The main limitation of our study was the small number of
environmental strains and non-R. mucilaginosa species tested.
Further studies are needed to confirm if these microorganisms
really have a lower capability to produce biofilm than clinical
strains of R. mucilaginosa.
Overall, the CV staining was a useful method to indirectly mea-
FIG 3 Scanning electron microscopy (SEM) images of 3 R.mucilaginosa isolates after the induction of biofilm formation on a PVC strip. Isolate 320, low biofilm
producer (A and B); isolate 3166, medium biofilm producer (C and D); and isolate 2991B, high biofilm producer (E and F). Absorbance values at 570 nm obtained
for each isolate subjected to the crystal violet staining assay are provided at the top of micrographics. Micrographics B, D, and F are higher magnifications of A,
C, and E, respectively. SEM images confirmed the CV staining interpretive criteria to indirectly quantify bulk biofilm production by Rhodotorula species isolates.
TABLE 3 In vitro activity of five antifungal agents against 50 clinical isolates of Rhodotorula species using the CLSI broth microdilution assay
Rhodotorula species
(no. of isolates)
Cell
incubation
period (h)
MIC (g/ml) for indicated antifungal agenta
AMB CAS VRC PSC FLC
MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 Range
R. mucilaginosa (44) 48 1 1 0.25–1 8 8 1–16 1 2 0.25–2 2 2 0.5–4 64 64 64
72 1 1 0.5–1 8 16 4–16 2 4 0.5–4 2 4 1–8 64 64 64
R. glutinis (2) 48 ND ND 0.5 ND ND 4 ND ND 0.25 ND ND 1–2 ND ND 64
72 ND ND 0.5–1 ND ND 8 ND ND 0.25 ND ND 2 ND ND 64
R. minuta (2) 48 ND ND 0.5 ND ND 2 ND ND 4 ND ND 2 ND ND 64
72 ND ND 1 ND ND 4 ND ND 4 ND ND 2 ND ND 64
R. dairenensis (2) 48 ND ND 0.5–1 ND ND 16 ND ND 0.25–0.5 ND ND 2 ND ND 64
72 ND ND 0.5–1 ND ND 16 ND ND 0.5–1 ND ND 1–2 ND ND 64
a AMB, amphotericin B; CAS, caspofungin; VRC, voriconazole; PSC, posaconazole; FLC, fluconazole; ND, not determined.
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sure bulk biofilm, and the results of biofilm production were con-
firmed by SEM. It was also observed that the storage time of the
samples did not affect the biofilm formation capability of R. mu-
cilaginosa clinical isolates. This finding conflicts with the hypoth-
esis that the expression of virulence factors by fungi may be sub-
stantially impaired by long-term storage of strains (34, 35).
The antifungal susceptibility profiles obtained strongly suggest
that the genus Rhodotorula is not a target for FLC or CAS. Other
azole agents also showed poor activity (2 g/ml) against the
majority of the isolates tested. In contrast, AMB showed the best
activity in vitro. Overall, the results obtained here are in agreement
with previous studies and show that it is more appropriate to read
the susceptibility test of Rhodotorula species after 72 h of incuba-
tion (4, 7, 9, 12, 29, 36, 37).
In conclusion, we emphasized the importance of molecular
methods to correctly identify Rhodotorula species isolates and
non-R. mucilaginosa species in particular. R. mucilaginosa was the
most prevalent species among the clinical and environmental
samples. All Rhodotorula species isolates tested were susceptible to
AMB, suggesting that it should be considered the antifungal drug
of choice for the treatment of Rhodotorula species invasive infec-
tions. Finally, we demonstrated that Rhodotorula species are able
to form biofilms, which may play a role in the pathogenesis of
infections by this species.
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